BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. (BMRN) Stock Overview
Explore BioMarin Pharmaceutical Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
11.3B
P/E Ratio
21.71
EPS (TTM)
$2.70
ROE
0.09%
BMRN Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of BioMarin Pharmaceutical Inc. (BMRN) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 56.67, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $67.30.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 21.71 and a market capitalization of 11.3B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.